Singapore’s biomedical sector is expected to benefit after a sharp rise in pharmaceutical production, as companies anticipate US trade policy changes.
Singapore’s biopharmaceutical industry is expected to benefit after a surge in drug production as companies anticipate changes in U.S. trade policy.